RALLYBIO CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.87 USD | -2.09% |
|
-1.58% | -21.76% |
| May. 15 | JPMorgan Downgrades Rallybio to Neutral From Overweight | MT |
| May. 09 | Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 306.5 | 248.6 | 90.33 | 79.17 | - | - |
| Enterprise Value (EV) 1 | 306.5 | 191.6 | 65.83 | 59.87 | 1.665 | -58.83 |
| P/E ratio | -5.18 x | -3.14 x | -1.3 x | -1.13 x | -1.19 x | -4.44 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | -2.83 x | - | -1.05 x | -0.04 x | 1.32 x |
| EV / FCF | - | -3.34 x | -1.09 x | -2.6 x | -0.1 x | 3.46 x |
| FCF Yield | - | -29.9% | -91.6% | -38.4% | -1,021% | 28.9% |
| Price to Book | - | 1.23 x | 0.91 x | 1.31 x | 1.07 x | 0.95 x |
| Nbr of stocks (in thousands) | 32,130 | 37,838 | 37,794 | 41,449 | - | - |
| Reference price 2 | 9.540 | 6.570 | 2.390 | 1.910 | 1.910 | 1.910 |
| Announcement Date | 3/15/22 | 3/6/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | -67.72 | - | -57.29 | -46.13 | -44.73 |
| EBIT 1 | - | -45.65 | -67.88 | -78.93 | -60.17 | -47.53 | -44.84 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -45.51 | -65.58 | -72.52 | -61.9 | -57.81 | -96.5 |
| Net income 1 | -26.45 | -47.01 | -66.65 | -74.56 | -60.15 | -47.5 | -44.08 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -9.950 | -1.840 | -2.090 | -1.840 | -1.683 | -1.603 | -0.4300 |
| Free Cash Flow 1 | - | - | -57.34 | -60.28 | -23 | -17 | -17 |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 7/22/21 | 3/15/22 | 3/6/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | -17.05 | - | -20.04 | -19.33 | - | -19.79 | - | - | - | - | - |
| EBIT 1 | -12.31 | -14.32 | -17.62 | -18.86 | -17.09 | -18.37 | -20.08 | -19.36 | -21.11 | -19.79 | -15.17 | -13.03 | -13.4 | -11.7 | -12 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -12.19 | -14.11 | -17.24 | -18.24 | -15.99 | -16.76 | -18.41 | -17.73 | -19.63 | -18.34 | -15.42 | -14.21 | -15.69 | -11.16 | -11.56 |
| Net income 1 | -12.42 | -14.5 | -17.58 | -18.37 | -16.2 | -17.32 | -18.63 | -18.37 | -20.24 | -19.03 | -16.62 | -14.51 | -12.12 | -11.84 | -12.24 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.4200 | -0.4800 | -0.5700 | -0.6000 | -0.4600 | -0.4300 | -0.4600 | -0.4500 | -0.5000 | -0.4700 | -0.3938 | -0.3326 | -0.2520 | -0.3250 | -0.3300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/15/22 | 5/10/22 | 8/8/22 | 11/7/22 | 3/6/23 | 5/9/23 | 8/8/23 | 11/9/23 | 3/12/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 57 | 24.5 | 19.3 | 77.5 | 138 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -57.3 | -60.3 | -23 | -17 | -17 |
| ROE (net income / shareholders' equity) | - | - | -38.6% | -52.6% | -57.9% | -38.8% | -25% |
| ROA (Net income/ Total Assets) | - | - | -36.8% | -49% | -52.6% | -35.4% | -23.5% |
| Assets 1 | - | - | 181.3 | 152.2 | 114.3 | 134 | 187.7 |
| Book Value Per Share 2 | - | - | 5.320 | 2.630 | 1.460 | 1.780 | 2.010 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 7/22/21 | 3/15/22 | 3/6/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.91
USD
Average target price
13
USD
Spread / Average Target
+580.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.08% | 79.17M | |
| +29.77% | 49.46B | |
| +1.00% | 42.58B | |
| +49.45% | 42.49B | |
| -5.26% | 29.09B | |
| +13.68% | 26.61B | |
| -22.99% | 18.64B | |
| +8.22% | 13.16B | |
| +32.41% | 12.55B | |
| +24.01% | 12.1B |
- Stock Market
- Equities
- RLYB Stock
- Financials Rallybio Corporation